Full Breakdown
Datopotamab Deruxtecan (Datroway) Shows Promising Results in Treating Triple-Negative Breast Cancer
10/6/2025, 8:59:27 PM
Landmark Phase III Trial Results
Datopotamab deruxtecan (Dato-DXd; Datroway) has demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer (TNBC) who are ineligible for immunotherapy. These findings emerged from the phase 3 TROPION-Breast02 trial (NCT05374512), marking a pivotal moment in the treatment landscape for this aggressive cancer type. The trial involved 644 patients across multiple continents, including Africa, Asia, Europe, North America, and South America, and compared Dato-DXd to the investigator's choice of chemotherapy.
Trial Design and Results
TROPION-Breast02 is an open-label, multicenter study that enrolled patients who had not received prior chemotherapy for their metastatic or locally recurrent TNBC. Participants were randomly assigned to receive either Dato-DXd or standard chemotherapy options, including capecitabine, carboplatin, or paclitaxel. The dual primary endpoints of the study were OS and PFS, both of which showed statistically significant and clinically meaningful improvements with Dato-DXd compared to chemotherapy.
Susan Galbraith, Executive Vice President of Oncology Hematology R&D at AstraZeneca, emphasized the trial's significance, stating, "TROPION-Breast02 is the only trial ever to show an overall survival benefit in the first-line treatment of patients with metastatic TNBC for whom immunotherapy is not an option." Ken Takeshita, Global Head of R&D at Daiichi Sankyo, echoed this sentiment, highlighting that Dato-DXd is the first antibody-drug conjugate to achieve such results against chemotherapy in this patient population.
Implications for Treatment
Approximately 70% of patients with metastatic TNBC are not candidates for immunotherapy, making chemotherapy the standard first-line treatment. The results from TROPION-Breast02 could potentially transform treatment options for these patients, who historically have had poor prognoses, with median survival rates of only 12 to 18 months. The safety profile of Dato-DXd was consistent with previous trials, suggesting it could be a viable alternative to traditional chemotherapy.
AstraZeneca and Daiichi Sankyo plan to present the full data from the trial at an upcoming medical meeting and share it with regulatory authorities to expedite the drug's availability to patients.
Ongoing Development and Future Trials
The companies are also exploring Dato-DXd in three additional phase III trials, including combinations with the immunotherapy drug Imfinzi (durvalumab) for various stages of TNBC. These ongoing studies aim to further assess the efficacy of Dato-DXd in different treatment settings, potentially expanding its use beyond the current indications.
Conclusion
The TROPION-Breast02 trial results represent a significant advancement in the treatment of metastatic TNBC, offering hope to a patient population that has limited options. As AstraZeneca and Daiichi Sankyo continue to develop Dato-DXd, the findings may lead to a paradigm shift in how this challenging cancer is treated, ultimately improving outcomes for patients in need.
